Related Experiment Videos
Predicting and preventing post-ERCP pancreatitis
1Division of Gastroenterology, Duke University Medical Center, Box 3189, Durham, NC 27710, USA. Baill001@mc.duke.edu
Current Gastroenterology Reports
|March 20, 2002
Summary
Post-ERCP pancreatitis (PEP) is a severe complication. Strategies to predict and prevent PEP include avoiding unnecessary procedures, ensuring experienced endoscopists, and considering promising pharmacologic interventions like somatostatin or gabexate mesylate.
Area of Science:
- Gastroenterology
- Endoscopic Procedures
Background:
- Post-ERCP pancreatitis (PEP) is a significant and feared complication of endoscopic retrograde cholangiopancreatography (ERCP).
- Severe PEP cases contribute to substantial morbidity, mortality, and ERCP-related deaths.
- Accurate prediction and effective prevention of PEP remain critical clinical challenges.
Purpose of the Study:
- To review current understanding and strategies for the prediction and prevention of post-ERCP pancreatitis.
- To highlight advancements in diagnostic methods and promising therapeutic interventions for PEP.
Main Methods:
- Review of existing literature on ERCP complications, focusing on pancreatitis.
- Analysis of diagnostic markers, including serum amylase, cytokines, and novel urine tests.
- Evaluation of preventive strategies, encompassing procedural modifications and pharmacologic agents.
Main Results:
- Diagnostic accuracy for PEP has improved with serum amylase and evolving cytokine/acute-phase reactant tests.
- A rapid dipstick test for urinary trypsinogen-2 shows potential for sensitive and specific PEP diagnosis.
- Preventive measures include judicious use of ERCP, avoiding high-risk procedures, ensuring endoscopist expertise, and considering pharmacologic interventions.
Conclusions:
- PEP prediction and prevention are paramount in ERCP practice.
- While many pharmacologic interventions have failed, somatostatin, octreotide, and gabexate mesylate show promise.
- A multi-faceted approach combining careful patient selection, procedural technique, and potential pharmacotherapy is essential for mitigating PEP risk.